2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 217-219
Treatment Considerations, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Coagulant Drugs, Women’s Health, Biological Processes, Genomics, Diseases, Bleeding and Clotting, Hemophilia, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Registries, Study Population, Human, Pediatric
PAPER

604 Ongoing risk of factor VIII immunogenicity in children with severe hemophilia A receiving emicizumab prophylaxis

Bhavya S Doshi, MD, Anna Schwartz, BS2, Karen Zimowski, MD3, Megan Brown, MD, MSc4, Kelly Tickle, DNP5, Caroline Trotter, MSN, CPNP-PC/AC6, Prashant Raghavendran, DO7, Gary Woods, MD8, Robert F. Sidonio Jr, MD,MSc9, Michael H White, MD, MSc10, Shannon L. Meeks, MD11
1 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
2 Emory College of Arts & Sciences, Atlanta, Georgia, United States
3 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
4 Department of Pediatrics, Division of Hematology/Oncology, Penn State Health, Children's Hospital, Hershey, Pennsylvania, United States
5 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
6 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
7 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
8 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
9 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
10 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
11 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States

Introduction: Severe hemophilia A (HA) is an inherited bleeding disorder caused by F8 genetic variants resulting in undetectable factor VIII (FVIII) activity. The development of neutralizing anti-FVIII antibodies (“inhibitors”) to FVIII replacement therapy is the most significant treatment related complication. Historically, most persons with severe HA (PwSHA) receiving FVIII prophylaxis reached 150 FVIII exposure days (ED) before age 3 years, with a reported inhibitor incidence of 20-40%. Bispecific antibodies that mimic FVIII activity (e.g., emicizumab) circumvent the need for FVIII prophylaxis resulting in protracted FVIII exposure due to reduced bleeding rates. Consequently, the rate of inhibitor development in PwSHA started on emicizumab early in life is unknown.

Objectives: The primary objective of this study was to compare FVIII EDs and inhibitor development between PwSHA on emicizumab versus FVIII prophylaxis.

Methods: An IRB-approved single-center retrospective study was performed at the Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders of Emory. PwSHA born between 2014 and 2024 with at least one year of follow-up data or that met the inhibitor endpoint were included. Patients who started emicizumab due to inhibitor diagnosis (n=3), had unclear FVIII ED documentation (n=2), switched prophylaxis before endpoint (n=1), or with < 1 year of follow-up data (n=2) were excluded. Demographics (age, sex, race) and clinical data (F8 mutation, inhibitor development, and FVIII ED) were extracted from the clinical chart. The rate of inhibitor development in PwSHA on emicizumab (born 2016-2024) or FVIII (born 2014-2018) were compared along with F8 mutation, race, ED, and inhibitor titer. Data are reported as median (range) or n (%). Fisher’s exact test was used to compare proportions and Mann-Whitney tests for continuous variables.

Results: A total of 49 male PwSHA were included in the study. Initial prophylaxis was FVIII in 23 (46.9%) and emicizumab in 26 (53.1%). The age at emicizumab initiation was 0.6 (0.0-5.0) years vs. 1.1 (0.0-2.3) years for FVIII (p<0.01). FVIII EDs before prophylaxis initiation were the same in the emicizumab and FVIII cohorts at 2 (0-10) and 2 (0-43), respectively, p=0.73. Inhibitors were observed at similar rates in 9/26 (34.6%) PwSHA on emicizumab and 11/23 (47.8%) on FVIII prophylaxis (p=0.39). Inhibitors were high titer at diagnosis in 2/9 (22%) emicizumab and 4/11 (36%) FVIII patients (p=0.08). Inhibitor diagnosis occurred slightly earlier in the emicizumab cohort at 5 (2-13) EDs compared to FVIII at 19 (3-90) EDs, p=0.08. The median number of additional EDs whilst on emicizumab prophylaxis prior to inhibitor development was 2 (range 0-9). While 96% of the FVIII group reached ED 10, only 8/26 (32%) of the emicizumab group have reached ED 10 (p<0.001). The non-inhibitor emicizumab cohort has reached a median of 6 (0-37) EDs. The median initial inhibitor titer (2.0 [0.6-22.7] vs. 2.5 [0.7-27.5], p=0.44) and peak titer (9.2 [0.6-1000] vs. 2.6 [0.7-45.6], p=0.62) were similar in the emicizumab and FVIII cohorts, respectively.

The overall population was 49% White/Caucasian, 36.7% Black/African American, and 14.3% other or unknown. The emicizumab cohort had a higher proportion of PwSHA of White/Caucasian race (69.2% vs. 26.1%) and lower proportion of Black/African American (23.1% vs. 52.2%) or other races (7.7% vs. 21.7%) compared to the FVIII cohort (p=0.01). However, the racial breakdown in inhibitor positive PwSHA was similar in the FVIII and emicizumab groups (p=0.30). Rates of intron 22 inversion, large gene deletion, and premature stop codon “high risk” F8 mutations were similar in the FVIII and emicizumab cohorts irrespective of inhibitor status.

Conclusion: Our data, for the first time, support comparable FVIII inhibitor rates between minimally treated PwSHA started on emicizumab or FVIII prophylaxis. Notably, inhibitors developed at slightly fewer EDs with similar titers in the emicizumab cohort. The earlier EDs at inhibitor diagnosis may support the “danger theory” of FVIII immunogenicity and highlight the importance of studying immune changes with FVIII exposures in PwSHA on non-factor therapeutics. Given that ~70% of the emicizumab cohort has yet to reach ED 10, this cohort remains at risk for inhibitor development. Thus, the rate here may be an underestimate and bolster the importance of ongoing inhibitor surveillance in PwSHA on primary emicizumab prophylaxis.

Bhavya S Doshi, MD: ChronoLog - Honoraria; Sanofi - Consultancy (Includes expert testimony)